共 526 条
[1]
Kazui M(2009)Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 92-9
[2]
Nishiya Y(2008)Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine Drug Metab Pharmacokinet 23 412-420
[3]
Ishizuka T(2006)The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts Proc Natl Acad Sci U S A 103 11069-74
[4]
Hagihara K(2011)High Doses of Clopidogrel to Overcome Genetic Resistance (The CLOVIS-2 study) J Am Coll Cardiol Intv 4 392-402
[5]
Farid NA(2011)High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI JAMA 306 1215-23
[6]
Okazaki O(2011)Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis JAMA 306 1765-1774
[7]
Ikeda T(2009)Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 354-62
[8]
Kurihara A(2009)Influence of CYP2C19 polymorphism on antiplatelet effects of clopidogrel and long-term recurrent ischemic event occurrence JAMA 302 849-858
[9]
Hagihara K(2010)Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans J Clin Pharmacol 50 126-142
[10]
Nishiya Y(2004)Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities Drug Metab Dispos 32 821-827